Lurasidone Hydrochloride

Lurasidone Hydrochloride | Torrent Pharmaceuticals Intelligence | Humanexa

Evidence Sources

Source-backed references used to construct this page.

FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDA
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDA
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDA
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDA
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDA
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDA
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDA
FDA document
View source
EFFECT OF A DİETİTİAN-SUPERVİSED LOW-FODMAP DİET VERSUS STANDARD WRİTTEN ADVİCE ON GASTROİNTESTİNAL SYMPTOMS AND INFLAMMATORY BİOMARKERS İN IRRİTABLE BOWEL SYNDROME: A RANDOMİZED CONTROLLED TRİAL
ClinicalTrials.gov
FDA document
View source
Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-ce
ClinicalTrials.gov
FDA document
View source
Strategies to Decentralize Breast Ultrasound in Rwanda
ClinicalTrials.gov
FDA document
View source
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
ClinicalTrials.gov
FDA document
View source
[Ad hoc announcement pursuant to Art.
Roche
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Roche
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Roche
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMed
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMed
FDA document
View source
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMed
FDA document
View source
Green synthesis of ZnO nanoparticles using pomegranate husk extract: comparative evaluation of antioxidant, enzyme inhibition, and cytotoxic properties.
PubMed
FDA document
View source
Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA
FDA
FDA document
View source

Lurasidone Hydrochloride

Asset Overview

Company Context

Regulatory Timeline

Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA

Related Signals

Evidence Sources